MojiaBio, a global leader in green chemistry and sustainable biomanufacturing, has announced a strategic partnership with the Agency for Science, Technology and Research (A*STAR) to develop a state-of-the-art Sustainable Biomanufacturing Technology Platform (SBTP) with an investment of SGD 44.8 million. This initiative will position Singapore as a global hub for sustainable biomanufacturing, accelerating the transition to a circular bioeconomy and net-zero future.

Unlike traditional bio-based molecule production methods, the SBTP aims to achieve cost-parity with conventional chemical processes by leveraging low-cost renewable feedstocks such as methanol and ethylene glycol. This innovative approach enables the production of high-value bio-based molecules that can be used across diverse industries, including textiles, automotive, personal care, and coatings.

Building Singapore’s Capabilities in Green Biomanufacturing

With the global market for green chemicals projected to reach USD 200 billion (SGD 270 billion) by 2030, this collaboration will boost Singapore’s synthetic biology capabilities, ensuring the nation captures a significant share of the sustainable bioeconomy.

At the core of the SBTP is MojiaBio’s proprietary Cn+Bio™ pathway and OrthBio® bioconversion process, which enable the efficient conversion of renewable feedstocks into high-performance bio-based molecules. Developed in close collaboration with ASTAR Singapore Institute of Food and Biotechnology Innovation (ASTAR SIFBI), the SBTP will leverage cutting-edge enzyme engineering to enhance conversion efficiency, scalability, and sustainability.

“The SBTP is more than a production platform; it is a catalyst for a greener future,” said Dr. Ramon Gonzalez, Chief Scientific Officer at MojiaBio. “By partnering with A*STAR, we are accelerating the commercialisation of green 1,3-propanediol (PDO), which plays a crucial role in applications ranging from skincare products to biodegradable plastics.”

The initiative also integrates advanced synthetic biology and computational modelling expertise from the National University of Singapore (NUS), enabling precise enzyme and microbial strain engineering. Unlike conventional fermentation methods, this platform operates independently of host cell metabolism, significantly improving energy efficiency and reducing production costs.

Strategic Impact on Singapore’s Green Economy

Professor Tan Sze Wee, Assistant Chief Executive of A*STAR Biomedical Research Council, emphasized the importance of this collaboration:

“The SBTP represents a transformative step for Singapore’s sustainable biomanufacturing industry. By leveraging A*STAR’s expertise in synthetic biology, enzyme engineering, and public-private partnerships, we are paving the way for the growth of a resilient bioeconomy.”

Executive Vice President Lim Wey-Len of the Singapore Economic Development Board (EDB) highlighted the significance of industrial biotechnology in driving sustainability:

“The SBTP is a testament to Singapore’s position as a global hub for sustainable manufacturing. Through research collaborations and industrial partnerships, we aim to scale novel bio-based solutions that enhance quality of life while meeting sustainability commitments.”

Advancing the Global Transition Toward Sustainability

The SBTP aligns with the Singapore Green Plan 2030 and international climate goals, reinforcing Singapore’s leadership in sustainable innovation. Compared to conventional chemical production methods, bio-based molecules produced via the platform offer significant environmental advantages:

• Reduced energy consumption: Uses renewable feedstocks such as methanol and ethylene glycol, requiring less processing energy.

• Lower carbon footprint: Bio-based production cuts CO₂ emissions by approximately 60% compared to conventional processes.

• Minimal pollutants: Produces fewer harmful emissions, including nitrogen oxides (NOx) and sulfur oxides (SOx), reducing industrial pollution.

“This collaboration exemplifies our shared vision for a sustainable future,” added Dr. Gonzalez. “MojiaBio is also establishing its operational headquarters and a dedicated research laboratory in Singapore to fast-track the commercialization of other green chemicals, further reinforcing the nation’s bioeconomy.”